Gliflozins available in pharmacies, diabetologists say, "It simplifies access and adherence to treatment."

Buzzetti (SID): "It recognizes the value of these medications and signals greater autonomy in managing chronic conditions."

"The recent reclassification of gliflozins represents an important step towards making medicine more accessible to everyone, especially people with diabetes. The ability to distribute these treatments in community pharmacies, without the need for a treatment plan, truly marks a paradigm shift. It's not just a bureaucratic simplification—which already represents a huge step forward—but it also recognizes the value of these drugs in managing type 2 diabetes and preventing complications." This is how Raffaella Buzzetti, president of the Italian Society of Diabetes (SID), commented to Adnkronos Salute on the publication in the Official Journal on July 19 of the reclassification of gliflozins by the Italian Medicines Agency (AIFA), in Tier A of reimbursable products that can be purchased in pharmacies , eliminating treatment plans that are compiled by specialists.

"This is a sign that points toward greater autonomy for clinicians in managing and treating chronic conditions," Buzzetti observes. "For people with diabetes, simplifying the management of their condition can translate into greater adherence" to treatment, a "fundamental" condition for therapeutic success. As is well known, "poor adherence" to treatment is a problem encountered in the treatment of chronic diseases, because "there are so many medications to take," explains the SID president. "The easier it is to obtain medications," such as at the local pharmacy, "the greater the willingness of the person with diabetes," in this case, "to obtain them and therefore to follow the therapy. In fact, if the person simply needs to contact the local community," especially if "they live in rural or mountainous areas" far from hospitals, "it certainly facilitates their daily life" and access to treatment.

"In a universal healthcare system like ours," Buzzetti emphasizes, "ensuring fair and timely access to care is not only a clinical but also an ethical responsibility. This is a truly important point. Simplifying prescription methods, if accompanied by training, not only does not weaken spending control, but certainly promotes the smooth running of care. Streamlining certainly does not mean trivializing and giving less importance," he specifies, "but it means making the system more easily usable. As specialists of the Italian Society of Diabetes, who treat people with diabetes every day, we know very well" that "prescribing treatment plans and bureaucratic delays certainly do not help. Simplifying access is therefore not just a bureaucratic act," he emphasizes, "but I would define it as an act of care, because as in all chronic diseases, the first 'medicine' is precisely the possibility of being treated" by having "easy" access to care and "medication, regardless of the region in which one lives," but also "whether one lives in the city, the countryside, or even in the countryside." in the mountains".